Cabaletta Bio, Inc. (CABA) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

Market Cap

$581.15M

MomentumView details →

1D Return

−1.50%

YTD Return

+56.85%

RSI (14)

62.6

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.2x

Market Cap

$581.15M

RSI (14)

62.6

MomentumView details →

1D Return

−1.50%

YTD Return

+56.85%

SummaryUpdated Jun 1, 2026

Cabaletta Bio, Inc. (NASDAQ:CABA) is a clinical-stage biotechnology company founded in 2017 and headquartered in Philadelphia, Pennsylvania. Originally incorporated as Tycho Therapeutics, Inc., the company changed its name to Cabaletta Bio in August 2018 and went public in October 2019. Cabaletta focuses on developing engineered T cell therapies specifically designed to treat B cell-mediated autoimmune diseases, representing a novel approach in the rapidly evolving field of cellular immunotherapy.

Ask drillr about Cabaletta Bio, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−86.10%

ROA (TTM)

−70.63%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+42.34%

FCF YoY

−45.14%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+29.91%

EBITDA YoY

−25.63%

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

8.82%

Beats (12Q)

5/12

Next Q EPS Est

−$0.32

Avg Surprise (4Q)

5.50%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.12x

Current Ratio

5.79x

Quick Ratio

5.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−181.32M

Op. CF (TTM)

−153.93M

Next earningsNov 9, 2026 →

Latest newsMore news →

Cabaletta Bio reported a net loss of $51.0 million for Q2 2026, with diluted EPS of -$0.34, and cash and investments of approximately $225.1 million as of June 30, 2026, expected to fund operations through mid-2027.23d ago

Similar companies

Zura Bio LimitedZURA REGENXBIO Inc.RGNX Eikon Therapeutics, Inc. Common StockEIKN Tectonic Therapeutic, Inc.TECX Scribe Therapeutics Inc.SCTX Autolus Therapeutics plcAUTL Find similar companies →

Latest newsMore news →